RE: Post 13128
BIOMEDS is not only inaccurate - they are PUMPERS disguised as a news publication. Read all the news articles of late regarding MCLN - they boast of share prices in the stratosphere for a stock with nearly a billion O.S. Or I'll even allow the 600 mil figure to be used for the O.S. I haven't gotten a cogent answer to this. Nonetheless Biomeds listed a near-term target of 0.14 or .40. This, IMO, is bordering on the absurd.
A publication that holds a position in a company is going to slant their reportage in a positive direction. Therein lies a CONFLICT OF INTERESTS. If one looks at the last few press releases from MCLN - they are articles from "Biomeds" , Rob Goldman (paid analyst) and "Skymark Research" which is also disguised as "Emerging Stock Report". Why two names for the same exact publication?
Where in the "Biomeds" report does it state that there have been no new contracts as of late and that the executives are working from their homes?
Where is it stated that their N.J. offices have been or will be closed in the very near future and that all mail addressed to MCLN at this office is received at a local P.O. Box by the CFO, who works from her home?
I would hold anything "Biomeds" reports as highly suspect due to their position in MCLN. They promote rumors (see NWCI) with no substantiation and those who take their written word as truth are being mislead.
This post is in no way construed to promote or dissuade anyone from opening or closing a position in MCLN or any other equity. Do your own DD and make your own decisions, please. It's your MONEY!
Market Data 
Markets 
